ELVN-001 / Enliven Therap  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ELVN-001 / Enliven Therap
ACTRN12624000115538: A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part A

Not yet recruiting
1
15
 
Enliven Therapeutics, Inc. , Enliven Therapeutics, Inc.
Chronic Myeloid Leukaemia (CML), Parkinson's Disease (PD)
 
 
ACTRN12624000116527: A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part B

Not yet recruiting
1
15
 
Enliven Therapeutics, Inc. , Enliven Therapeutics, Inc.
Chronic Myeloid Leukaemia (CML), Parkinson's Disease (PD)
 
 
ACTRN12623000760673: Study to Assess the Safety, Tolerability and Pharmacokinetics Of ELVN-001 In Normal Healthy Participants

Recruiting
1
80
 
Enliven Therapeutics, Inc., Enliven Therapeutics, Inc.
Chronic Myeloid Leukamia
 
 
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia
12/26
12/26

Download Options